The multidrug resistance pump ABCB1 is a substrate for the ubiquitin ligase NEDD4-1

Molecular Membrane Biology

Volumn 32, Issue 2, 2015, Pages 39-45

  Akkaya, Begum G ^a   Zolnerciks, Joseph K ^a   Ritchie, Tasha K ^a   Bauer, Bjoern ^b   Hartz, Anika M S ^c,d   Sullivan, James A ^e   Linton, Kenneth J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Department of Pharmaceutical Sciences   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ABCB1; Alzheimer's disease; amyloid protein; blood brain barrier; Nedd4; P glycoprotein; ubiquitin ligase

Indexed keywords

AMYLOID BETA PROTEIN; LYSINE; MULTIDRUG RESISTANCE PROTEIN 1; RECOMBINANT PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; ABCB1 PROTEIN, HUMAN; ESCRT PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME MECHANISM; ESCHERICHIA COLI; HEK293 CELL LINE; INSECT CELL; MALE; MASS SPECTROMETRY; MOLECULAR MODEL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; TRANSIENT EXPRESSION; UBIQUITINATION; ANIMAL; BRAIN; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SF9 CELL LINE; TRANSGENIC MOUSE; VASCULARIZATION;

ESCHERICHIA COLI; HEXAPODA; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BINDING SITES; BLOOD-BRAIN BARRIER; BRAIN; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HEK293 CELLS; HUMANS; LYSINE; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; P-GLYCOPROTEINS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SF9 CELLS; UBIQUITIN-PROTEIN LIGASES;

EID: 84939424072     PISSN: 09687688     EISSN: 14645203     Source Type: Journal    
DOI: 10.3109/09687688.2015.1023378     Document Type: Article

References (31)

1. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
2. Anan T, Nagata Y, Koga H, Honda Y, Yabuki N, Miyamoto C, et al. 1998. Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. Genes to Cells 3:751-763.
3. Barsnes H, Vaudel M, Colaert N, Helsens K, Sickmann A, Berven FS, Martens L. 2011. compomics-utilities: an open-source Java library for computational proteomics. BMC Bioinformatics 12:70.
4. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Investigation 115:3285-3290.
5. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344.
6. Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, et al. 2000. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Human Molec Genetics 9:1209-1217.
7. Fu D, Roufogalis BD. 2007. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol Cell Physiol 292:C1543-C1552.
8. Hartz AM, Miller DS, Bauer B. 2010. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Molec Pharmacol 77:715-723.
9. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
10. Ingham RJ, Gish G, Pawson T. 2004. The Nedd4 family of E3 ubiquitin ligases: Functional diversity within a common modular architecture. Oncogene 23:1972-1984.
11. Jeynes B, Provias J. 2011. An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis. Neurosci Lett 487:389-393.
12. Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, et al. 2009. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci 29: 4964-4971.
13. Katayama K, Noguchi K, Sugimoto Y. 2013. FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells. Cancer Sci 104:694-702.
14. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. 2007. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17: 347-353.
15. Martin CA, Longman E, Wooding C, Hoosdally SJ, Ali S, Aitman TJ, et al. 2007. Cd36, a class B scavenger receptor, functions as a monomer to bind acetylated and oxidized low-density lipoproteins. Protein Sci 16:2531-2541.
16. Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, et al. 1989. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biolog Chem 264: 18031-18040.
17. Muller C, Laurent G, Ling V. 1995. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cellular Physiol 163:538-544.
18. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I. 1988. Stability and covalent modification of P-glycoprotein in multidrugresistant KB cells. Biochemistry 27:7607-7613.
19. Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerciks JK, Atkins WM, Sligar SG. 2009. Chapter 11: Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Meth Enzymol 464:211-231.
20. Rotin D, Kumar S. 2009. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 10:398-409.
21. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. 1995. Characterization of a novel protein-binding module-the WW domain. FEBS Lett 369:67-71.
22. Sudol M, Hunter T. 2000. NeW wrinkles for an old domain. Cell 103: 1001-1004.
23. Sullivan JA, Lewis MJ, Nikko E, Pelham HR. 2007. Multiple interactions drive adaptor-mediated recruitment of the ubiquitin ligase rsp5 to membrane proteins in vivo and in vitro. Molecul Biol Cell 18:2429-2440.
24. Taylor AM, Storm J, Soceneantu L, Linton KJ, Gabriel M, Martin C, et al. 2001. Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 134:1609-1618.
25. Vaudel M, Barsnes H, Berven FS, Sickmann A, Martens L. 2011. SearchGUI: An open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. Proteomics 11:996-999.
26. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. 2002. Deposition of Alzheimer's betaamyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12: 535-541.
27. Yoshimura A, Kuwazuru Y, Sumizawa T, Ikeda S, Ichikawa M, Usagawa T, Akiyama S. 1989. Biosynthesis, processing and half-life of P-glycoprotein in a human multidrug-resistant KB cell. Biochim et Biophys Acta 992:307-314.
28. Zhang Z, Wu JY, Hait WN, Yang JM. 2004. Regulation of the stability of P-glycoprotein by ubiquitination. Molec Pharmacol 66:395-403.
29. Zlokovic BV. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201.
30. Zolnerciks JK, Akkaya BG, Snippe M, Chiba P, Seelig A, Linton KJ. 2014. The Q loops of the human multidrug resistance transporter ABCB1 are necessary to couple drug binding to the ATP catalytic cycle. FASEB J 28:4335-4346.
31. Zolnerciks JK, Wooding C, Linton KJ. 2007. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J 21:3937-3948.